Overall, these studies suggest that lung inflammatory factors, like IL-6 and macrophages, and dysfunction of lung epithelial cells can alter MSC activity, indicating that the identification of disease microenvironments and the modification of naïve MSCs are both crucial in the development of effective MSC therapy for ARDS. The gene discussed is IL6; the disease is acute respiratory distress syndrome.